A new HIV prevention drug will be made available at a lower cost in over 100 low-income countries within two years, a move expected to give millions access to the breakthrough treatment and potentially bring the world closer to ending the HIV/Aids epidemic.
The drug, called Lenacapavir and administered by injection, is due to be rolled out as early as the end of this year, for $28,000 (£20,000) per person annually.
But Wednesday’s announcement promises to slash that price to just $40, around 0.1% of the original cost.
The lower-cost version will be rolled out in 2027 across 120 low and middle-income countries.
Scientists say the drug stops the virus from replicating inside cells.
The landmark deal to provide cheaper antiretroviral drugs for people with HIV in developing countries was brokered by former US President Bill Clinton after negotiations with pharmaceutical companies.
The agreement announced on Wednesday was reached between the Clinton Foundation in partnership with the Gates Foundation and other groups, including South Africa’s research institute, Wits RHI.
Lenacapavir has delivered impressive trial results and, in July, it received official backing from the World Health Organization (WHO) for HIV prevention.
The injection is taken twice a year and provides six months of protection against HIV infection at a time.
Experts say long-acting injectables like Lenacapavir could help reduce new infections in populations that are most vulnerable, including adolescent girls and young women, LGBT people, sex workers, and those who use drugs.
It is hoped it will replace the current form of HIV preventative drug, known as PrEP, or pre-exposure prophylaxis, which is taken orally and also costs $40 per person each year.
The pills are taken daily, which can be difficult for patients to consume, and can carry stigma in certain societies.
Read also:
- Bayelsa CSOs train community volunteers to tackle Malaria, TB, HIV in grassroots health push
- Cross River intensifies campaigns to curb HIV/AIDS spread
- Ebonyi Aids Coordinator seeks Government funding for HIV/AIDS, Hepatitis, others
The daily dose also makes it harder to access consistently. According to the Gates Foundation, only 18% of those who could benefit from PrEP currently have access.
Lenacapavir has already been approved by the US Food and Drug Administration and the European Commission this year.
Last June, the US drug company Gilead announced that a trial of its HIV drug Lenacapavir had a 100% success rate.
The new, generic version is still pending regulatory approval, but it is hoped it will be available within 18 months.
One study says that increasing access to the injection to just 4% of the population could prevent up to 20% of new HIV infections.
The drug can be used to protect people from catching the virus, but also to treat those who have it, according to scientists.
